Y-Biologics (XKRX:338840) Net Margin % : -2,373.10% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Y-Biologics's Net Income for the three months ended in Dec. 2023 was ₩-14,620 Mil. Y-Biologics's Revenue for the three months ended in Dec. 2023 was ₩616 Mil. Therefore, Y-Biologics's net margin for the quarter that ended in Dec. 2023 was -2,373.10%.

The historical rank and industry rank for Y-Biologics's Net Margin % or its related term are showing as below:

XKRX:338840' s Net Margin % Range Over the Past 10 Years
Min: -1047.5 Med: -435.04 Max: -148.98
Current: -529.44

XKRX:338840's Net Margin % is ranked worse than
65.44% of 1030 companies
in the Biotechnology industry
Industry Median: -154.79 vs XKRX:338840: -529.44

Y-Biologics Net Margin % Historical Data

The historical data trend for Y-Biologics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Net Margin % Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

Get a 7-Day Free Trial

-1,047.50

-830.17

-148.98

-352.17

-453.06

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial			-472.61	-342.07	-634.20	-26.91	-2,373.10

Competitive Comparison of Y-Biologics's Net Margin %

For the Biotechnology subindustry, Y-Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-Biologics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Net Margin % falls into.

Y-Biologics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Y-Biologics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-18804.401	/	4150.558
	=	-453.06 %

Y-Biologics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-14620.308	/	616.084
	=	-2,373.10 %

Y-Biologics (XKRX:338840) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Y-Biologics Net Margin % Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines